73 publications
Name | Date | Type | Actions |
---|---|---|---|
Vétoquinol and Orion Pharma Animal Health enter into distribution collaboration Vétoquinol and Orion Pharma Animal Health - a part of Orion Corporation - announce their collaboration regarding the distribution of Dexdomitor®, Antisedan®, Domitor® and Domosedan®. Vétoquinol becomes distributor in selected European countries of these Orion Sedative products. |
Public releases | ||
2014 sales up 5.2% to €315.3 million The Vétoquinol Group posted 2014 sales of €315.3 million, up 5.2% from the previous year. At constant exchange rates, sales rose by 6.3%. The Vétoquinol Group achieved organic growth of 1.4% in 2014. |
Public releases | ||
Monthly information regarding the total number of voting rights and shares making of the share capital - December 2014 As per article 223.16 of the « Règlement Général de l’Autorité des Marchés Financiers » |
Voting rights | ||
Vétoquinol markets CEFTIOCYL® and KEFLORIL® two new injectable antibiotics for livestock Lure, December 15, 2010 – In line with recent announcements, Vétoquinol is |
Public releases | ||
Monthly information regarding the total number of voting rights and shares making of the share capital - November 2010 As per article 223.16 of the « Règlement Général de l’Autorité des Marchés Financiers » |
Voting rights | ||
November 30, 2010 (Lure, France) – Vétoquinol has appointed Régis Vimal du Monteil as |
Public releases | ||
Vétoquinol registers its injectable Marbocyl® 2% and Marbocyl® 10% antibiotics in Japan November 18, 2010 (Lure, France) – Vétoquinol has just obtained Marketing |
Public releases | ||
Monthly information regarding the total number of voting rights and shares making of the share capital - October2010 As per article 223.16 of the « Règlement Général de l’Autorité des Marchés Financiers » |
Voting rights | ||
Strong Sales in the 3rd Quarter of 2010 Vétoquinol’s revenues for the third quarter of 2010 rose by 10.8%. This healthy rate of growth was attributable mainly to strong performance in the Group’s strategic regions and therapeutic segments. |
Public releases | ||
Monthly information regarding the total number of voting rights and shares making of the share capital - September 2010 As per article 223.16 of the « Règlement Général de l’Autorité des Marchés Financiers » |
Voting rights |